Weekly injections under the skin of the experimental therapy survodutide significantly reduces the severity of metabolic-associated steatohepatitis (MASH), a severe form of fatty…
While highly effective treatments for hepatitis C are available worldwide, many people — especially those living in poorer countries — are not able to access…
Chemomab Therapeutics has been awarded patents in Brazil and Israel covering CM-101, the company’s experimental therapy that’s currently being tested in a Phase…
Intrahepatic cholestasis of pregnancy (ICP), a liver disorder that can affect a pregnant woman, leads to abnormally high levels of a protein called ERp29…
In infants with suspected cholestasis, targeted single-gene testing for those with symptoms that indicate a particular, associated disease and broader gene panel testing for…
Seladelpar, an experimental oral therapy by CymaBay Therapeutics, significantly lowered blood levels of an itch-associated molecule called interleukin-31 (IL-31) in people with…
In a wide-ranging analysis of thousands of different proteins from liver samples from transplant patients, a team of scientists in Spain discovered potential links to…
Denifanstat, Sagimet Biosciences’ experimental therapy, outperformed a placebo at resolving nonalcoholic steatohepatitis (NASH) — a severe form of fatty liver disease —…
